Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

HRAS

From Wikipedia, the free encyclopedia
Protein-coding gene in humans
This article is about the gene and protein it encodes. For the singular of HRAs, seeHRA (disambiguation).
HRAS
Available structures
PDBOrtholog search:PDBeRCSB
List of PDB id codes

121P,1AA9,1AGP,1BKD,1CLU,1CRP,1CRQ,1CRR,1CTQ,1GNP,1GNQ,1GNR,1HE8,1IAQ,1IOZ,1JAH,1JAI,1K8R,1LF0,1LF5,1LFD,1NVU,1NVV,1NVW,1NVX,1P2S,1P2T,1P2U,1P2V,1PLJ,1PLK,1PLL,1Q21,1QRA,1RVD,1WQ1,1XCM,1XD2,1XJ0,1ZVQ,1ZW6,221P,2C5L,2CE2,2CL0,2CL6,2CL7,2CLC,2CLD,2EVW,2LCF,2LWI,2Q21,2QUZ,2RGA,2RGB,2RGC,2RGD,2RGE,2RGG,2UZI,2VH5,2X1V,3DDC,3I3S,3K8Y,3K9L,3K9N,3KKM,3KKN,3KUD,3L8Y,3L8Z,3LBH,3LBI,3LBN,3LO5,3OIU,3OIV,3OIW,3RRY,3RRZ,3RS0,3RS2,3RS3,3RS4,3RS5,3RS7,3RSL,3RSO,421P,4DLR,4DLS,4DLT,4DLU,4DLV,4DLW,4DLX,4DLY,4DLZ,4EFL,4EFM,4EFN,4G0N,4G3X,4K81,4Q21,521P,5P21,621P,6Q21,721P,821P,4L9S,4L9W,4NYI,4NYJ,4NYM,4URU,4URV,4URW,4URX,4URY,4URZ,4US0,4US1,4US2,2N42,2N46,4XVQ,4XVR,4RSG,5B30

Identifiers
AliasesHRAS, C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV, HRAS1, RASH1, p21ras, Harvey rat sarcoma viral oncogene homolog, HRas proto-oncogene, GTPase, RASK2
External IDsOMIM:190020;MGI:96224;HomoloGene:55890;GeneCards:HRAS;OMA:HRAS - orthologs
Gene location (Human)
Chromosome 11 (human)
Chr.Chromosome 11 (human)[1]
Chromosome 11 (human)
Genomic location for HRAS
Genomic location for HRAS
Band11p15.5Start532,242bp[1]
End537,321bp[1]
Gene location (Mouse)
Chromosome 7 (mouse)
Chr.Chromosome 7 (mouse)[2]
Chromosome 7 (mouse)
Genomic location for HRAS
Genomic location for HRAS
Band7 F5|7 86.48 cMStart140,769,018bp[2]
End140,773,918bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • skin of abdomen

  • skin of leg

  • putamen

  • caudate nucleus

  • nucleus accumbens

  • Hypothalamus

  • Temporal Lobe

  • Amygdala

  • right hemisphere of cerebellum

  • substantia nigra
Top expressed in
  • dentate gyrus of hippocampal formation granule cell

  • lip

  • molar

  • superior frontal gyrus

  • esophagus

  • fetal liver hematopoietic progenitor cell

  • yolk sac

  • entorhinal cortex

  • perirhinal cortex

  • muscle of thigh
More reference expression data
BioGPS




More reference expression data
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo /QuickGO
Orthologs
SpeciesHumanMouse
Entrez

3265

15461

Ensembl

ENSG00000276536
ENSG00000174775

ENSMUSG00000025499

UniProt

P01112

Q61411

RefSeq (mRNA)

NM_001130442
NM_005343
NM_176795
NM_001318054

NM_001130443
NM_001130444
NM_008284

RefSeq (protein)

NP_001123914
NP_001304983
NP_005334
NP_789765

NP_001123915
NP_001123916
NP_032310

Location (UCSC)Chr 11: 0.53 – 0.54 MbChr 7: 140.77 – 140.77 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

GTPase HRas, from "Harvey Rat sarcoma virus", also known astransforming protein p21 is anenzyme that in humans is encoded by theHRASgene.[5][6] TheHRAS gene is located on the short (p) arm ofchromosome 11 at position 15.5, frombase pair 522,241 to base pair 525,549.[7] HRas is asmall G protein in theRas subfamily of theRas superfamily ofsmall GTPases. Once bound toGuanosine triphosphate, H-Ras will activate aRaf kinase likec-Raf, the next step in theMAPK/ERK pathway.

Function

[edit]

GTPase HRas is involved in regulating cell division in response togrowth factor stimulation.Growth factors act by binding cell surfacereceptors that span the cell's plasma membrane. Once activated, receptors stimulate signal transduction events in thecytoplasm, a process by which proteins and second messengers relay signals from outside the cell to the cell nucleus and instructs the cell to grow or divide. The HRAS protein is aGTPase and is an early player in many signal transduction pathways and is usually associated withcell membranes due to the presence of anisoprenyl group on itsC-terminus. HRAS acts as a molecular on/off switch, once it is turned on it recruits and activates proteins necessary for the propagation of the receptor's signal, such asc-Raf andPI 3-kinase. HRAS binds toGTP in the active state and possesses an intrinsic enzymatic activity that cleaves the terminal phosphate of this nucleotide converting it toGDP. Upon conversion of GTP to GDP, HRAS is turned off. The rate of conversion is usually slow but can be sped up dramatically by an accessory protein of the GTPase activating protein (GAP) class, for exampleRasGAP. In turn HRAS can bind to proteins of the Guanine Nucleotide Exchange Factor (GEF) class, for exampleSOS1, which forces the release of bound nucleotide. Subsequently, GTP present in thecytosol binds and HRAS-GTP dissociates from the GEF, resulting in HRAS activation. HRAS is in theRas family, which also includes two other proto-oncogenes:KRAS andNRAS. These proteins all are regulated in the same manner and appear to differ largely in their sites of action within the cell.

Clinical significance

[edit]
See also:List of genes mutated in pigmented cutaneous lesions

Costello syndrome

[edit]

At least five inheritedmutations in theHRAS gene have been identified in people withCostello syndrome. Each of these mutations changes an amino acid in a critical region of the HRAS protein. The most common mutation replaces theamino acidglycine with the amino acidserine at position 12 (written as Gly12Ser or G12S). The mutations responsible for Costello syndrome lead to the production of an HRAS protein that is permanently active. Instead of triggering cell growth in response to particular signals from outside the cell, the overactive protein directs cells to grow and divide constantly. This uncontrolled cell division can result in the formation of noncancerous and cancerous tumors. Researchers are uncertain how mutations in theHRAS gene cause the other features of Costello syndrome (such as mental retardation, distinctive facial features, and heart problems), but many of the signs and symptoms probably result from cell overgrowth and abnormal cell

Bladder cancer

[edit]

HRAS has been shown to be aproto-oncogene. When mutated, proto-oncogenes have the potential to cause normal cells to becomecancerous. Some gene mutations are acquired during a person's lifetime and are present only in certain cells. These changes are calledsomatic mutations and are not inherited. Somatic mutations in theHRAS gene in bladder cells have been associated withbladder cancer. One specific mutation has been identified in a significant percentage of bladder tumors; this mutation substitutes one protein building block (amino acid) for another amino acid in the HRAS protein. Specifically, the mutation replaces the amino acidglycine with the amino acidvaline at position 12 (written as Gly12Val, G12V, or H-RasV12). The altered HRAS protein is permanently activated within the cell. This overactive protein directs the cell to grow and divide in the absence of outside signals, leading to uncontrolled cell division and the formation of a tumor. Mutations in theHRAS gene also have been associated with the progression of bladder cancer and an increased risk of tumor recurrence after treatment.

Other cancers

[edit]

Somatic mutations in theHRAS gene are probably involved in the development of several other types of cancer. These mutations lead to an HRAS protein that is always active and can direct cells to grow and divide without control. Recent studies suggest thatHRAS mutations are common in thyroid, salivary duct carcinoma,[8] epithelial-myoepithelial carcinoma,[9] and kidney cancers. DNA copy-number gain of a segment containingHRAS is included in a genome-wide pattern, which was found to be correlated with anastrocytoma patient's outcome.[10][11]The HRAS protein also may be produced at higher levels (overexpressed) in other types of cancer cells.

References

[edit]
  1. ^abcENSG00000174775 GRCh38: Ensembl release 89: ENSG00000276536, ENSG00000174775Ensembl, May 2017
  2. ^abcGRCm38: Ensembl release 89: ENSMUSG00000025499Ensembl, May 2017
  3. ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^Wong-Staal F, Dalla-Favera R, Franchini G, Gelmann EP, Gallo RC (Jul 1981). "Three distinct genes in human DNA related to the transforming genes of mammalian sarcoma retroviruses".Science.213 (4504):226–8.Bibcode:1981Sci...213..226W.doi:10.1126/science.6264598.PMID 6264598.
  6. ^Russell MW, Munroe DJ, Bric E, Housman DE, Dietz-Band J, Riethman HC, Collins FS, Brody LC (Jul 1996)."A 500-kb physical map and contig from the Harvey ras-1 gene to the 11p telomere".Genomics.35 (2):353–60.doi:10.1006/geno.1996.0367.PMID 8661149.
  7. ^"Entrez Gene: v-Ha-ras Harvey rat sarcoma viral oncogene homolog".
  8. ^Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, Luvison A, Roy S, Seethala RR, Nikiforova MN (Jun 2015). "Molecular characterization of apocrine salivary duct carcinoma".The American Journal of Surgical Pathology.39 (6):744–52.doi:10.1097/PAS.0000000000000410.PMID 25723113.S2CID 34106002.
  9. ^Chiosea SI, Miller M, Seethala RR (Jun 2014)."HRAS mutations in epithelial-myoepithelial carcinoma".Head and Neck Pathology.8 (2):146–50.doi:10.1007/s12105-013-0506-4.PMC 4022927.PMID 24277618.
  10. ^K. A. Aiello; O. Alter (October 2016)."Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition".PLOS ONE.11 (10): e0164546.Bibcode:2016PLoSO..1164546A.doi:10.1371/journal.pone.0164546.PMC 5087864.PMID 27798635.
  11. ^K. M. Reily; D. A. Loisel; R. T. Bronson; M. E. McLaughlin; T. Jacks (September 2000). "Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects".Nature Genetics.26 (1):109–113.doi:10.1038/79075.PMID 10973261.S2CID 23076620.

Further reading

[edit]

External links

[edit]
PDB gallery
  • 121p: STRUKTUR UND GUANOSINTRIPHOSPHAT-HYDROLYSEMECHANISMUS DES C-TERMINAL VERKUERZTEN MENSCHLICHEN KREBSPROTEINS P21-H-RAS
    121p: STRUKTUR UND GUANOSINTRIPHOSPHAT-HYDROLYSEMECHANISMUS DES C-TERMINAL VERKUERZTEN MENSCHLICHEN KREBSPROTEINS P21-H-RAS
  • 1aa9: HUMAN C-HA-RAS(1-171)(DOT)GDP, NMR, MINIMIZED AVERAGE STRUCTURE
    1aa9: HUMAN C-HA-RAS(1-171)(DOT)GDP, NMR, MINIMIZED AVERAGE STRUCTURE
  • 1agp: THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLY-12 MUTANT OF P21-H-RAS
    1agp: THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLY-12 MUTANT OF P21-H-RAS
  • 1bkd: COMPLEX OF HUMAN H-RAS WITH HUMAN SOS-1
    1bkd: COMPLEX OF HUMAN H-RAS WITH HUMAN SOS-1
  • 1clu: H-RAS COMPLEXED WITH DIAMINOBENZOPHENONE-BETA,GAMMA-IMIDO-GTP
    1clu: H-RAS COMPLEXED WITH DIAMINOBENZOPHENONE-BETA,GAMMA-IMIDO-GTP
  • 1crp: THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
    1crp: THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
  • 1crq: THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
    1crq: THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
  • 1crr: THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
    1crr: THE SOLUTION STRUCTURE AND DYNAMICS OF RAS P21. GDP DETERMINED BY HETERONUCLEAR THREE AND FOUR DIMENSIONAL NMR SPECTROSCOPY
  • 1ctq: STRUCTURE OF P21RAS IN COMPLEX WITH GPPNHP AT 100 K
    1ctq: STRUCTURE OF P21RAS IN COMPLEX WITH GPPNHP AT 100 K
  • 1gnp: X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
    1gnp: X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
  • 1gnq: X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
    1gnq: X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
  • 1gnr: X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
    1gnr: X-RAY CRYSTAL STRUCTURE ANALYSIS OF THE CATALYTIC DOMAIN OF THE ONCOGENE PRODUCT P21H-RAS COMPLEXED WITH CAGED GTP AND MANT DGPPNHP
  • 1he8: RAS G12V - PI 3-KINASE GAMMA COMPLEX
    1he8: RAS G12V - PI 3-KINASE GAMMA COMPLEX
  • 1iaq: C-H-RAS P21 PROTEIN MUTANT WITH THR 35 REPLACED BY SER (T35S) COMPLEXED WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE
    1iaq: C-H-RAS P21 PROTEIN MUTANT WITH THR 35 REPLACED BY SER (T35S) COMPLEXED WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE
  • 1ioz: Crystal Structure of the C-HA-RAS Protein Prepared by the Cell-Free Synthesis
    1ioz: Crystal Structure of the C-HA-RAS Protein Prepared by the Cell-Free Synthesis
  • 1jah: H-RAS P21 PROTEIN MUTANT G12P, COMPLEXED WITH GUANOSINE-5'-[BETA,GAMMA-METHYLENE] TRIPHOSPHATE AND MAGNESIUM
    1jah: H-RAS P21 PROTEIN MUTANT G12P, COMPLEXED WITH GUANOSINE-5'-[BETA,GAMMA-METHYLENE] TRIPHOSPHATE AND MAGNESIUM
  • 1jai: H-RAS P21 PROTEIN MUTANT G12P, COMPLEXED WITH GUANOSINE-5'-[BETA,GAMMA-METHYLENE] TRIPHOSPHATE AND MANGANESE
    1jai: H-RAS P21 PROTEIN MUTANT G12P, COMPLEXED WITH GUANOSINE-5'-[BETA,GAMMA-METHYLENE] TRIPHOSPHATE AND MANGANESE
  • 1k8r: Crystal structure of Ras-Bry2RBD complex
    1k8r: Crystal structure of Ras-Bry2RBD complex
  • 1lf0: Crystal Structure of RasA59G in the GTP-bound form
    1lf0: Crystal Structure of RasA59G in the GTP-bound form
  • 1lf5: Crystal Structure of RasA59G in the GDP-bound Form
    1lf5: Crystal Structure of RasA59G in the GDP-bound Form
  • 1lfd: CRYSTAL STRUCTURE OF THE ACTIVE RAS PROTEIN COMPLEXED WITH THE RAS-INTERACTING DOMAIN OF RALGDS
    1lfd: CRYSTAL STRUCTURE OF THE ACTIVE RAS PROTEIN COMPLEXED WITH THE RAS-INTERACTING DOMAIN OF RALGDS
  • 1nvu: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
    1nvu: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
  • 1nvv: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
    1nvv: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
  • 1nvw: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
    1nvw: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
  • 1nvx: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
    1nvx: Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS
  • 1p2s: H-Ras 166 in 50% 2,2,2 triflouroethanol
    1p2s: H-Ras 166 in 50% 2,2,2 triflouroethanol
  • 1p2t: H-Ras 166 in Aqueous mother liquor, RT
    1p2t: H-Ras 166 in Aqueous mother liquor, RT
  • 1p2u: H-Ras in 50% isopropanol
    1p2u: H-Ras in 50% isopropanol
  • 1p2v: H-RAS 166 in 60 % 1,6 hexanediol
    1p2v: H-RAS 166 in 60 % 1,6 hexanediol
  • 1plj: CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
    1plj: CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
  • 1plk: CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
    1plk: CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
  • 1pll: CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
    1pll: CRYSTALLOGRAPHIC STUDIES ON P21H-RAS USING SYNCHROTRON LAUE METHOD: IMPROVEMENT OF CRYSTAL QUALITY AND MONITORING OF THE GTPASE REACTION AT DIFFERENT TIME POINTS
  • 1q21: CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF THE CATALYTIC DOMAINS OF NORMAL RAS PROTEIN AND AN ONCOGENIC MUTANT COMPLEXED WITH GSP
    1q21: CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF THE CATALYTIC DOMAINS OF NORMAL RAS PROTEIN AND AN ONCOGENIC MUTANT COMPLEXED WITH GSP
  • 1qra: STRUCTURE OF P21RAS IN COMPLEX WITH GTP AT 100 K
    1qra: STRUCTURE OF P21RAS IN COMPLEX WITH GTP AT 100 K
  • 1rvd: H-RAS COMPLEXED WITH DIAMINOBENZOPHENONE-BETA,GAMMA-IMIDO-GTP
    1rvd: H-RAS COMPLEXED WITH DIAMINOBENZOPHENONE-BETA,GAMMA-IMIDO-GTP
  • 1wq1: RAS-RASGAP COMPLEX
    1wq1: RAS-RASGAP COMPLEX
  • 1xcm: Crystal structure of the GppNHp-bound H-Ras G60A mutant
    1xcm: Crystal structure of the GppNHp-bound H-Ras G60A mutant
  • 1xd2: Crystal Structure of a ternary Ras:SOS:Ras*GDP complex
    1xd2: Crystal Structure of a ternary Ras:SOS:Ras*GDP complex
  • 1xj0: Crystal Structure of the GDP-bound form of the RasG60A mutant
    1xj0: Crystal Structure of the GDP-bound form of the RasG60A mutant
  • 1zvq: Structure of the Q61G mutant of Ras in the GDP-bound form
    1zvq: Structure of the Q61G mutant of Ras in the GDP-bound form
  • 1zw6: Crystal Structure of the GTP-bound form of RasQ61G
    1zw6: Crystal Structure of the GTP-bound form of RasQ61G
  • 221p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
    221p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
  • 2c5l: STRUCTURE OF PLC EPSILON RAS ASSOCIATION DOMAIN WITH HRAS
    2c5l: STRUCTURE OF PLC EPSILON RAS ASSOCIATION DOMAIN WITH HRAS
  • 2ce2: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP
    2ce2: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP
  • 2cl0: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GPPNHP
    2cl0: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GPPNHP
  • 2cl6: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH S-CAGED GTP
    2cl6: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH S-CAGED GTP
  • 2cl7: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP
    2cl7: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP
  • 2clc: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP (2)
    2clc: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP (2)
  • 2cld: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP (2)
    2cld: CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP (2)
  • 2evw: Crystal structure analysis of a fluorescent form of H-Ras p21 in complex with R-caged GTP
    2evw: Crystal structure analysis of a fluorescent form of H-Ras p21 in complex with R-caged GTP
  • 2q21: CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF THE CATALYTIC DOMAINS OF NORMAL RAS PROTEIN AND AN ONCOGENIC MUTANT COMPLEXED WITH GSP
    2q21: CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF THE CATALYTIC DOMAINS OF NORMAL RAS PROTEIN AND AN ONCOGENIC MUTANT COMPLEXED WITH GSP
  • 421p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
    421p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
  • 4q21: MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION: STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS
    4q21: MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION: STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS
  • 521p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
    521p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
  • 5p21: REFINED CRYSTAL STRUCTURE OF THE TRIPHOSPHATE CONFORMATION OF H-RAS P21 AT 1.35 ANGSTROMS RESOLUTION: IMPLICATIONS FOR THE MECHANISM OF GTP HYDROLYSIS
    5p21: REFINED CRYSTAL STRUCTURE OF THE TRIPHOSPHATE CONFORMATION OF H-RAS P21 AT 1.35 ANGSTROMS RESOLUTION: IMPLICATIONS FOR THE MECHANISM OF GTP HYDROLYSIS
  • 621p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
    621p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
  • 6q21: MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION: STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS
    6q21: MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION: STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS
  • 721p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
    721p: THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES
  • 821p: THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLYCINE-12 MUTANT OF P21H-RAS
    821p: THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLYCINE-12 MUTANT OF P21H-RAS
Ligand
Growth factors
ONCO
Receptor
Wnt signaling pathway
TSP
Hedgehog signaling pathway
TSP
TGF beta signaling pathway
TSP
Receptor tyrosine kinase
ONCO
JAK-STAT signaling pathway
ONCO
Intracellular signaling P+Ps
Wnt signaling pathway
ONCO
TSP
TGF beta signaling pathway
TSP
Akt/PKB signaling pathway
ONCO
TSP
Hippo signaling pathway
TSP
MAPK/ERK pathway
ONCO
TSP
Other/unknown
ONCO
TSP
Nucleus
Cell cycle
ONCO
TSP
DNA repair/Fanconi
TSP
Ubiquitin ligase
ONCO
TSP
Transcription factor
ONCO
TSP
Mitochondrion
Apoptosis inhibitor
Other/ungrouped
3.6.1
3.6.2
3.6.3-4:ATPase
3.6.3
Cu++ (3.6.3.4)
Ca+ (3.6.3.8)
Na+/K+ (3.6.3.9)
H+/K+ (3.6.3.10)
OtherP-type ATPase
3.6.4
3.6.5:GTPase
3.6.5.1:Heterotrimeric G protein
3.6.5.2:Small GTPase >Ras superfamily
3.6.5.3:Protein-synthesizing GTPase
3.6.5.5-6:Polymerization motors
MAP
Calcium
G protein
Heterotrimeric
cAMP:
cGMP:
Monomeric
Cyclin
Lipid
Otherprotein kinase
Serine/threonine:
Tyrosine:
Serine/threonine/tyrosine
Arginine
Otherprotein phosphatase
Serine/threonine:
Tyrosine:
both:
Apoptosis
GTP-binding protein regulators
Other
Retrieved from "https://en.wikipedia.org/w/index.php?title=HRAS&oldid=1228768472"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp